ORIGIN trial shows safety and efficacy of insulin glargine: no adverse cardiovascular outcomes after a 6.2-year follow up of early insulin use.
作者信息
Lombard Landi, Distiller Larry, Aalbers Julia
出版信息
Cardiovasc J Afr. 2012 Jul;23(6):357-8.
PMID:23091824
Abstract
摘要
相似文献
1
ORIGIN trial shows safety and efficacy of insulin glargine: no adverse cardiovascular outcomes after a 6.2-year follow up of early insulin use.
Cardiovasc J Afr. 2012 Jul;23(6):357-8.
2
Basal insulin and cardiovascular and other outcomes in dysglycemia.
N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.
3
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.
4
The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial.
Diab Vasc Dis Res. 2017 Jul;14(4):345-352. doi: 10.1177/1479164117703034. Epub 2017 Apr 12.
5
Comments on ORIGIN trial.
Nutr Metab Cardiovasc Dis. 2013 Aug;23(8):e33-4. doi: 10.1016/j.numecd.2013.03.002. Epub 2013 Jun 17.
6
Learning from ORIGIN.
J Diabetes. 2012 Sep;4(3):191-2. doi: 10.1111/j.1753-0407.2012.00215.x.
7
[Early insulin therapy in type 2 diabetes?].
Tidsskr Nor Laegeforen. 2012 Oct 16;132(19):2151-2. doi: 10.4045/tidsskr.12.0866.
8
Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial.
J Diabetes Complications. 2014 Jul-Aug;28(4):553-8. doi: 10.1016/j.jdiacomp.2014.02.012. Epub 2014 Mar 2.
9
Basal insulin and cardiovascular and other outcomes.
N Engl J Med. 2012 Nov 1;367(18):1763; author reply 1763-4. doi: 10.1056/NEJMc1210553.
10
Basal insulin and cardiovascular and other outcomes.
N Engl J Med. 2012 Nov 1;367(18):1762; author reply 1763-4. doi: 10.1056/NEJMc1210553.
Zotero 插件